Documente Academic
Documente Profesional
Documente Cultură
Marketing Finance
Powered by
Page 1
Copyright Equidam 2019
COMPANY PROFILE
Data Matrix Limited
Core Business
Started in: 2015
Professional services in clinical data management: CRF Data base customization Data verification
Incorporated: Yes
Query tracking Data coding according to MedDRA and WHO Drug Adverse experience data
Year of incorporation: 2018
reconciliation
Country: United Kingdom
Team
Scalability: Yes
Competitive products are: On the same level and we innovate in terms of execution
Investment proposal
Powered by
Page 2
Copyright Equidam 2019
COMPANY PROFILE
Shareholders
Key figures
Latest operating performance Ratios
Assets Liabilities
Elevator pitch
Our products automate the processes of clinical trial, the users manage and monitor its progress online. We adjust and validate our software before the project
start, R&D costs are reduced by 15%.
Powered by
Page 3
Copyright Equidam 2019
VALUATION
£ 19,007,475
£ 18,141,026
£ 5,669,754
£ 3,055,707 £ 3,493,111
Scorecard Method Check-List Method Venture Capital Method DCF with LTG DCF with Multiples
Valuation weights
of the 5 methods implemented in this analysis. The weights are set according
to the stage of development of the start-up: the later the
stage and the higher the influence of analytical models given
6% 6% 16% 36% 36% the higher reliability of the financial projections. Users may
however prefer one method over another in determining their
valuation estimate.
Powered by
Page 4
Copyright Equidam 2019
VALUATION
20.3%
for an investment of
£ 3,100,000
17.9% 23.3%
Powered by
Page 5
Copyright Equidam 2019
QUALITATIVE METHODS
100%
87.5%
78.57%
75%
58.33%
50% 50% 50% 50% 50% 50% 50%
CRITERIA
Strength of the team 78.57%
Size of the Opportunity 75%
Strength and protection of the product/service 100%
Competitive Environment 58.33%
Strategic relationships with partners 87.5%
Funding required 50%
ASSUMPTIONS
Starting value of this method (Average Company Valuation) £ 1,817,521
Powered by
Page 6
Copyright Equidam 2019
QUALITATIVE METHODS
63.9%
a a a a a a
CRITERIA
Quality of the core team 86%
Quality of the Idea 64%
Product roll-out and IP protection 100%
Strategic Relationships 92%
Operating Stage 100%
ASSUMPTIONS
Maximum value for this method £ 4,000,000
Powered by
Page 7
Copyright Equidam 2019
FINANCIAL FORECASTS
Revenues
01/2019 - 12/2019 01/2020 - 12/2020 01/2021 - 12/2021
Average estimate
The stage of development of the company
allows for the estimation of expected
£ 5,000,000
performance. The risk involved is however
very high since there is no track_record.
£ 3,500,000
£ 2,200,000
EBIT
£ 2,258,186
£ 1,375,731
£ 753,602
Powered by
Page 8
Copyright Equidam 2019
VC METHOD DCF WITH LTG DCF WITH MULTIPLES
£ 2,750,000
EBITDA Year 3
£ 861,632
21.6
£ 224,236
Industry multiple
49%
£ 18,141,026 discount rate per year
Pre-money valuation
14.6% £ 3,100,000
Equity Investment
percentage
CRITERIA
Exit value in year 3 £ 59,526,900
ASSUMPTIONS
Annual discount rate applied 48.6%
Powered by
Page 9
Copyright Equidam 2019
VC METHOD DCF WITH LTG DCF WITH MULTIPLES
£ 1,578,277
41.11%
£ 861,632
58.89%
26.4%
£ 224,236
Survival rate 8.85%
91.15%
12.9% 2.5 %
£ 7,651,835 Discount rate Long-Term Growth
25.9%
CRITERIA
EBITDA Year 3 £ 2,750,000
Long Term Growth Winsorized* 2.5%
Value of the company in the last Year (Terminal Value) £ 9,118,918
*Winsorization is a statistic approach that eliminates the outliers from a dataset by applying a lower and higher bound. In this case is necessary since some of the industries
in the Equidam database have a negative historical growth.
ASSUMPTIONS
Beta 2.03
Market Risk Premium 5.7%
Weighted Average Cost of Capital 12.95%
Powered by
Page 10
Copyright Equidam 2019
VC METHOD DCF WITH LTG DCF WITH MULTIPLES
£ 1,578,277
41.11%
£ 2,750,000
EBITDA Year 3
£ 861,632 58.89%
26.4%
X
Cash flow table
73.6%
Failure rate
21.6
Survival rate £ 224,236
8.85% Industry multiple
91.15%
12.9%
25.9%
CRITERIA
EBITDA Year 3 £ 2,750,000
EBITDA multiple Year 3 21.65
Value of the company in the last Year (Terminal Value) £ 35,055,391
Implied Annual Return if sale value realized (ROI) 16.61%
ASSUMPTIONS
Beta 2.03
Market Risk Premium 5.7%
Weighted Average Cost of Capital 12.95%
Powered by
Page 11
Copyright Equidam 2019
PROFIT AND LOSS CASH FLOW
01/2019 - 12/2019 01/2020 - 12/2020 01/2021 - 12/2021
Financial Gain-Loss £0 £0 £0
Debt interest payment £0 £0 £0
Powered by
Page 12
Copyright Equidam 2019
PROFIT AND LOSS CASH FLOW
01/2019 - 12/2019 01/2020 - 12/2020 01/2021 - 12/2021
Powered by
Page 13
Copyright Equidam 2019
APPENDIX
Estimated revenues in the third year according to the stage of the development
Estimated size of the market in three years
Geographical scope of the business
Powered by
Page 14
Copyright Equidam 2019
APPENDIX
Operating stage
Stage of development
Current profitability
Powered by
Page 15
Copyright Equidam 2019
About this report
Equidam BV does not represent or endorse the accuracy or reliability of any advice, opinion, statement or any other information
displayed or distributed through this report or its website. The estimates and the data contained herein are made using the
information provided by the user, publicly available information and data for different industries. Equidam BV has not audited or
attempted to confirm this information for accuracy or completeness. Under no circumstances the present report is to be used or
considered as an offer, solicitation, or recommendation to sell, or a solicitation of any offer to buy any security. Equidam BV
excludes any warranties and responsibilities concerning the results to be obtained from the present report nor their use and
shall not be liable for any claims, losses or damages arising from or occasioned by any inaccuracy, error, delay, or omission, or
from use of the report or actions taken in reliance on the information contained in it. The use of this report and the information
provided herein is subject to Equidam BV online Terms of Use and Privacy Policy.